Tag - MDP

Markets

Raymond James starts Medexus at OP; PT $5.50 (Canadian)

Raymond James initiated coverage of Medexus Pharmaceuticals (TSX:MDP) with an “outperform” rating and price target of $5.50 (Canadian). The stock closed at $3.32 on Feb. 18. Medexus is a fully integrated, specialty...

February 22, 2022

Markets

Mackie Research ups Medexus Pharma PT to $9 (Canadian) from $6.30

Mackie Research Capital raised its price target for Medexus Pharmaceuticals (TSXV:MDP; OTCQX:MEDXF) to $9 (Canadian) from $6.30, citing positive momentum in sales of the company’s key drugs. The stock closed at $6.11 on...

December 15, 2020

Markets

Mackie cuts Medexus Pharma to speculative buy; PT to $8.70 from $10.50

Mackie Research downgraded Medexus Pharmaceuticals (TSXV:MDP; OTCQB:PDDPF) to “speculative buy” from “buy” and lowered its price target to $8.70 (Canadian) from $10.50 after the company acquired Ixinity, a recombinant...

March 2, 2020

Tag - MDP

Raymond James starts Medexus at OP; PT $5.50 (Canadian)

Mackie Research ups Medexus Pharma PT to $9 (Canadian) from $6.30

Mackie cuts Medexus Pharma to speculative buy; PT to $8.70 from $10.50

General

More